Research programme: HBV cccDNA formation inhibitors - Arbutus Biopharma
Alternative Names: ARB-199; ARB-596; cccDNA formation inhibitors - Arbutus; Covalently closed circular DNA formation inhibitors - ArbutusLatest Information Update: 28 Mar 2018
At a glance
- Originator Baruch S. Blumberg Institute; Drexel University College of Medicine
- Developer Arbutus Biopharma; Baruch S. Blumberg Institute
- Class Antivirals; Small molecules
- Mechanism of Action Hepatitis B virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Mar 2018 No recent reports of development identified for research development in Hepatitis-B in USA (PO)
- 30 Aug 2016 Arbutus terminates its licence for VLP technology with Kuros
- 19 Nov 2014 OnCore Biopharma and Baruch S Blumberg Institute enter into a research collaboration to develop treatments for Hepatitis B and Liver cancer